190 related articles for article (PubMed ID: 27375010)
1. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.
Theis F; Corbacioglu A; Gaidzik VI; Paschka P; Weber D; Bullinger L; Heuser M; Ganser A; Thol F; Schlegelberger B; Göhring G; Köhne CH; Germing U; Brossart P; Horst HA; Haase D; Götze K; Ringhoffer M; Fiedler W; Nachbaur D; Kindler T; Held G; Lübbert M; Wattad M; Salih HR; Krauter J; Döhner H; Schlenk RF; Döhner K
Leukemia; 2016 Nov; 30(11):2248-2250. PubMed ID: 27375010
[No Abstract] [Full Text] [Related]
2. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
[TBL] [Abstract][Full Text] [Related]
3. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.
Green CL; Tawana K; Hills RK; Bödör C; Fitzgibbon J; Inglott S; Ancliff P; Burnett AK; Linch DC; Gale RE
Br J Haematol; 2013 Jun; 161(5):701-705. PubMed ID: 23560626
[TBL] [Abstract][Full Text] [Related]
4. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.
Fasan A; Eder C; Haferlach C; Grossmann V; Kohlmann A; Dicker F; Kern W; Haferlach T; Schnittger S
Leukemia; 2013 Feb; 27(2):482-5. PubMed ID: 22814295
[No Abstract] [Full Text] [Related]
5. Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia.
Shiba N; Funato M; Ohki K; Park MJ; Mizushima Y; Adachi S; Kobayashi M; Kinoshita A; Sotomatsu M; Arakawa H; Tawa A; Horibe K; Tsukimoto I; Hayashi Y
Br J Haematol; 2014 Jan; 164(1):142-5. PubMed ID: 24033149
[No Abstract] [Full Text] [Related]
6. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
[TBL] [Abstract][Full Text] [Related]
7. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
Mulet-Lazaro R; van Herk S; Erpelinck C; Bindels E; Sanders MA; Vermeulen C; Renkens I; Valk P; Melnick AM; de Ridder J; Rehli M; Gebhard C; Delwel R; Wouters BJ
Blood; 2021 Jul; 138(2):160-177. PubMed ID: 33831168
[TBL] [Abstract][Full Text] [Related]
8. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations.
Marceau-Renaut A; Guihard S; Castaigne S; Dombret H; Preudhomme C; Cheok M
Am J Hematol; 2015 May; 90(5):E93-4. PubMed ID: 25611491
[No Abstract] [Full Text] [Related]
9. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
[TBL] [Abstract][Full Text] [Related]
10. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
11. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
Heyes E; Wilhelmson AS; Wenzel A; Manhart G; Eder T; Schuster MB; Rzepa E; Pundhir S; D'Altri T; Frank AK; Gentil C; Woessmann J; Schoof EM; Meggendorfer M; Schwaller J; Haferlach T; Grebien F; Porse BT
Nat Commun; 2023 Oct; 14(1):6185. PubMed ID: 37794021
[TBL] [Abstract][Full Text] [Related]
12. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
14. Inherited predisposition to acute myeloid leukemia.
Godley LA
Semin Hematol; 2014 Oct; 51(4):306-21. PubMed ID: 25311743
[TBL] [Abstract][Full Text] [Related]
15. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
16. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia.
Tien FM; Hou HA; Tsai CH; Tang JL; Chiu YC; Chen CY; Kuo YY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Lin CT; Wu SJ; Ko BS; Hsu SC; Huang SY; Yao M; Chou WC; Tien HF
Blood Cancer J; 2018 Aug; 8(9):87. PubMed ID: 30190467
[TBL] [Abstract][Full Text] [Related]
17. [CEBPA gene mutation analysis in acute myeloid leukemia].
Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt-Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia.
Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Farsani MA
Ann Hum Genet; 2017 Nov; 81(6):276-283. PubMed ID: 28895127
[TBL] [Abstract][Full Text] [Related]
19. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and genetic background of familial myelodysplasia and acute myeloid leukemia].
Király PA; Kállay K; Marosvári D; Benyó G; Szőke A; Csomor J; Bödör C
Orv Hetil; 2016 Feb; 157(8):283-9. PubMed ID: 26876264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
